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Heavy metal 
deposition in 
gadolinium-associated 
systemic fibrosis
Gadolinium-based contrast agents 
are a mainstay of clinical investiga-
tion. Hence, it came as a shock when 
scientists discovered that these agents 
are the likely cause of a new syndrome 
called nephrogenic systemic fibrosis, a 
serious and disabling disease. Swami-
nathan et al. investigated its cause by 
examining the records of patients who 
had an exposure to the contrast media. 
Autopsies of three patients who died 
of this condition showed heavy metal 
deposits in the hearts, blood vessels, 
and skin. When these deposits were 
examined by mass spectrometry and 
X-ray fluorescence, they were found to 
be composed of gadolinium, iron, and 
aluminum. Of the 32 patients studied, 
10 died of cardiovascular events such 
as congestive heart failure, recurrent 
arrhythmias, hypotension, stroke, limb 
ischemia,  posterior ischemic optic 
neuropathy, or sudden death. While 
the gadolinium deposits could easily 
be rationalized, the cause of iron and 
aluminum in the deposits remains 
unknown. Further, these studies raise 
the question of whether chelation 
therapy might be a useful treatment. 
See page 1413.
A marker of disease 
progression in  
IgA nephropathy
Progression of immunoglobulin A (IgA) 
nephropathy to renal failure is diﬃcult 
to predict; as a result, identiﬁcation of 
markers is needed. To that end, van Es 
et al. studied renal biopsies taken from 
patients with early stages of IgA nephro-
pathy. They focused on inﬁltration with 
B- and T-lymphocyte cells, which were 
classiﬁed on the basis of their expression 
of a variety of markers. One such marker 
was the granule membrane protein of 
17 kDa (GMP-17), which identified 
cytotoxic T cells, macrophages, ﬁbro-
blasts, and tubulointerstitial expression 
of human leukocyte antigen-D related 
antigens. The patients had heterogeneous 
initial glomerular filtration rates and 
rates of progression on follow-up. The 
authors tabulated levels of mesangial 
proliferation, tubular atrophy, intersti-
tial ﬁbrosis, and interstitial inﬁltrates. 
They found that the presence of GMP-
17-positive cytotoxic T lymphocytes in 
intact renal tubules and the presence of 
B lymphocytes in the interstitium were 
the most important predictors of pro-
gression to renal failure. These studies 
not only suggest that GMP-17-positive 
cells are a good marker of renal failure, 
but they identify a population of cyto-
toxic cells that may provide insight into 
the mechanism of disease progression. 
See page 1426.
IL-13 in ischemia–
reperfusion injury
Following ischemic injury, reperfusion 
causes inflammatory cells to invade 
the kidney, secreting mediators that 
are thought to be the major cause of 
injury. As they report in this issue, 
Sandovici et al. used gene therapy to 
induce overexpression of interleukin 
(IL)-13, a cytokine well known to have 
anti-inﬂammatory actions. The authors 
tested whether its overexpression pro-
tected the kidney from ischemic injury. 
They infused rats with an adenovirus 
containing the IL-13 gene and found 
that plasma levels increased 50-fold. 
When ischemia–reperfusion was then 
performed on the animals, it decreased 
expression of kidney injury molecule-1, 
a biomarker for injury, as well as histo-
logical anomalies. Remarkably, inﬁltra-
tion by neutrophils and macrophages 
and the amount of interstitial ﬁbrosis 
were largely reduced. Expression of other 
inﬂammatory mediators, such as IL-8, 
macrophage inflammatory protein-2, 
tumor necrosis factor-α, and mono-
cyte chemoattractant protein-1 mRNA 
was also reduced. These studies sug-
gest that IL-13 might provide an excel-
lent therapeutic agent for acute kidney 
injury induced by ischemia–reperfusion. 
See page 1364.
